Cannabinoid CB 2 receptors (CB 2 Rs) have been recently reported to modulate brain dopamine (DA)-related behaviors; however, the cellular mechanisms underlying these actions are unclear. Here we report that CB 2 Rs are expressed in ventral tegmental area (VTA) DA neurons and functionally modulate DA neuronal excitability and DA-related behavior. In situ hybridization and immunohistochemical assays detected CB 2 mRNA and CB 2 R immunostaining in VTA DA neurons. Electrophysiological studies demonstrated that activation of CB 2 Rs by JWH133 or other CB 2 R agonists inhibited VTA DA neuronal firing in vivo and ex vivo, whereas microinjections of JWH133 into the VTA inhibited cocaine self-administration. Importantly, all of the above findings observed in WT or CB 1 −/− mice are blocked by CB 2 R antagonist and absent in CB 2 −/− mice. These data suggest that CB 2 R-mediated reduction of VTA DA neuronal activity may underlie JWH133's modulation of DA-regulated behaviors.
T he presence of functional cannabinoid CB 2 receptors (CB 2 Rs) in the brain has been controversial. When CB 2 Rs were first cloned, in situ hybridization (ISH) failed to detect CB 2 mRNA in brain (1) . Similarly, Northern blot and polymerase chain reaction (PCR) assays failed to detect CB 2 mRNA in brain (2) (3) (4) (5) . Therefore, CB 2 Rs were considered "peripheral cannabinoid receptors" (1, 6) .
In contrast, other studies using ISH and radioligand binding assays detected CB 2 mRNA and receptor binding in rat retina (7) , mouse cerebral cortex (8) , and hippocampus and striatum of nonhuman primates (9) . More recent studies using RT-PCR also detected CB 2 mRNA in the cortex, striatum, hippocampus, amygdala, and brainstem (9) (10) (11) (12) (13) (14) . Immunoblot and immunohistochemistry (IHC) assays detected CB 2 R immunoreactivity or immunostaining in various brain regions (13, (15) (16) (17) (18) (19) (20) . The specificities of the detected CB 2 R protein and CB 2 -mRNA remain questionable, however, owing to a lack of controls using CB 1 −/− and CB 2 −/− mice in most previous studies (21) . A currently accepted view is that brain CB 2 Rs are expressed predominantly in activated microglia during neuroinflammation, whereas brain neurons, except for a very small number in the brainstem, lack CB 2 R expression (21) .
On the other hand, we recently reported that brain CB 2 Rs modulate cocaine self-administration and cocaine-induced increases in locomotion and extracellular dopamine (DA) in the nucleus accumbens in mice (22) . This finding is supported by recent studies demonstrating that systemic administration of the CB 2 R agonist O-1966 inhibited cocaine-induced conditioned place preference in WT mice, but not in CB 2 −/− mice (23) , and that increased CB 2 R expression in mouse brain attenuates cocaine self-administration and cocaine-enhanced locomotion (19) . In addition, brain CB 2 Rs may be involved in several DA-related CNS disorders, such as Parkinson's disease (24) , schizophrenia (25) , anxiety (26) , and depression (27) . The cellular mechanisms underlying CB 2 R modulation of DA-related behaviors and diseases are unclear, however. Given that midbrain DA neurons of the ventral tegmental area (VTA) play an important role in mediating the reinforcing and addictive effects of drugs of abuse (28, 29) , we hypothesized that brain CB 2 Rs, similar to other G protein-coupled receptors, are expressed in VTA DA neurons, where they modulate DA neuronal function and DA-related behaviors.
In the present study, we tested this hypothesis using multiple approaches. We first assayed for CB 2 mRNA and protein expression in brain and in VTA DA neurons using quantitative RT-PCR (qRT-PCR), ISH, and double-label IHC techniques. We then examined the effects of the selective CB 2 R agonist JWH133 and several other CB 2 R agonists on VTA DA neuronal firing in both ex vivo and in vivo preparations using electrophysiological methods. Finally, we observed the effects of microinjections of JWH133 into the VTA on intravenous cocaine self-administration to study whether activation of VTA CB 2 Rs modulates DA-dependent behavior. This multidisciplinary approach has provided evidence of functional CB 2 Rs in VTA DA neurons. Importantly, all findings observed in WT or CB 1 −/− mice
Significance
Although early studies suggested that cannabinoid CB 2 receptors (CB 2 Rs) are absent in the brain, this view has been challenged by recent findings of significant brain CB 2 R involvement in several dopamine (DA)-related CNS disorders. The cellular mechanisms underlying these actions are unclear, however. Using multiple approaches, we found that CB 2 R genes and receptors are expressed in midbrain DA neurons, and that activation of CB 2 Rs inhibits DA neuronal firing and i.v. cocaine selfadministration. These findings not only challenge the long-held view that brain CB 2 Rs are not expressed in neurons, but also suggest that neuronal CB 2 Rs modulate DA neuronal activity and DA-regulated behavior. Thus, brain CB 2 Rs may constitute a new therapeutic target in medication development for treatment of a number of CNS disorders.
were blocked by a CB 2 R antagonist and/or absent in CB 2 −/− mice, suggesting that CB 2 Rs expressed in VTA DA neurons play an important role in modulating DA neuronal activity and DArelated functions.
Results CB 2 mRNA Is Expressed in the Brain. We first used qRT-PCR to examine CB 2 mRNA expression in the brain and spleen of WT, CB 1 −/− , and CB 2 −/− mice using three different TaqMan probes targeting different gene sequences ( Fig. 1 and Table S1 ). Fig. 1 shows the gene structure, two mouse CB 2 R transcripts (CB 2A and CB 2B ), the CB 2 gene-deleted region in CB 2 −/− mice (6), and three probes used to detect CB 2 mRNA in WT, CB 1 −/− , and CB 2 −/− mice. When using the probes that target the conjunction region of exons 1 and 3 (CB 2A probe) or exons 2 and 3 (CB 2B probe), we detected similar or even higher levels of CB 2A and CB 2B mRNA in prefrontal cortex, striatum, midbrain, and spleen in CB 2 −/− mice compared with WT mice (Fig. 1C , Left and Middle); however, when using the CB 2 -KO probe that targets the deleted gene sequence in CB 2 −/− mice (Fig. 1B) , we detected CB 2 mRNA in WT and CB 1 −/− mice, but not in CB 2 −/− mice (Fig. 1C, Right) . Further quantitative assays indicated that CB 2A mRNA was ∼60 times lower in cortex than in spleen (Fig. 1C , Left) , and that CB 2B mRNA was ∼500 times lower in cortex than in spleen (Fig. 1C , Middle).
CB 2 mRNA Is Expressed in VTA DA Neurons. Based on the foregoing findings, we successfully developed a CB 2 -specific riboprobe targeting the gene-deleted regions in the presently used CB 2 −/− mice to examine CB 2 mRNA expression in VTA DA neurons. In this experiment, we first used traditional ISH methods (SI Experimental Procedures) to examine CB 2 mRNA in VTA neurons, and then performed IHC assays with tyrosine hydroxylase (TH) antibody to identify the phenotype(s) of CB 2 mRNA-positive neurons. We found that the antisense riboprobe detected CB 2 mRNA signaling in the midbrain of WT and CB 1 −/− mice, but not CB 2 −/− mice ( Fig. 2 A, b) , and that the corresponding CB 2 -mRNA sense (control) probe did not detect any mRNA signal (Fig. 2 A, b) . Fig. 2 A, c shows representative ISH-IHC images in the VTA, illustrating detection of CB 2 mRNA staining in VTA DA neurons (TH-positive) in WT mice, but not in CB 2 −/− mice, suggesting that CB 2 R mRNA is expressed in VTA DA neurons.
To confirm this finding, we used another highly-sensitive RNAscope ISH method, which allowed us to simultaneously detect TH mRNA and CB 2 mRNA in VTA neurons. In this experiment, we initially designed two RNAscope probes that target the deleted gene sequences in CB 2 −/− mice and the 3′ untranslated region (UTR) of the CB 2 gene, respectively. We found only one probe targeting the 3′ UTR (Fig. 2 B, a) that worked well. Fig. 2 B, b and c shows CB 2 mRNA staining in VTA DA (TH mRNA-positive) neurons in WT and CB 2 −/− mice using this RNAscope probe. This probe apparently detected CB 2 mRNA in CB 2 −/− mice, because it detected the intact 3′ UTR region located downstream of the gene-deleted sequence (Fig. 2 B, a) . Fig. S1 shows representative confocal images under high magnification, illustrating colocalization of CB 2 mRNA with TH mRNA in VTA DA neurons of WT and CB 2 −/− mice. In addition, CB 2 mRNA is also expressed in TH-negative VTA non-DA neurons (Fig. S1 ). Taken together, the , and CB 2 −/− mice. Fig. 3 A and B presents representative confocal images of mCB 2 R immunostaining using the NIH-5633 and Alomone mCB 2 antibodies that target the deleted intracellular third loop or the deleted C terminal of CB 2 Rs in CB 2 −/− mice, illustrating that CB 2 R staining was detected in VTA DA neurons in WT and CB 1 −/− mice, but barely detectable in CB 2 −/− mice. Preabsorption of the antibody with specific immune peptide blocked CB 2 R immunostaining in VTA DA neurons, suggesting that both antibodies are mCB 2 -specific. −/− strain is a partial CB 2 knockout mouse, (ii) both the NIH-5633 and Alomone mCB 2 antibodies display a significant degree of (but not absolute) mCB 2 R specificity, and (iii) the Abcam rCB 2 antibody specificity is unknown, because N terminal-containing CB 2 R fragment(s) may be present in this strain of CB 2 −/− mice.
CB 2 R Immunostaining Is Detected in Splenocytes, but Is Barely
Detectable in Glial Cells. We also used the same antibodies to detect CB 2 immunostaining in CB 2 -rich splenocytes. Fig. S4 shows that both the NIH-5633 and Alomone antibodies detected high densities of CB 2 immunostaining in splenocytes of WT mice, but very low densities in CB 2 −/− mice. Finally, we used the same antibodies to determine whether CB 2 receptors are expressed in glial cells. Fig. S5 shows that the NIH-5633 antibody detected a very low density of CB 2 immunostaining in GFAP-labeled astrocytes, but not in CD11b-labeled microglia, in mice treated with vehicle (saline) or lipopolysaccharide (LPS), a bacterial endotoxin. These data suggest that CB 2 Rs are expressed mainly in DA neurons rather than in glial cells in the VTA. (Fig. S6 ). Fig. 4 shows a representative dissociated TH-positive VTA DA neuron (Fig. 4A ) and characteristic low DA neuronal FR (∼1 Hz) (Fig. 4B) . JWH133 significantly reduced VTA DA neuronal firing in WT mice in a dose-dependent manner (Fig. 4 B and C, a; **P < 0.01, paired t test, compared with pre-JWH133 baseline). This effect was blocked by coadministration of the selective CB 2 R antagonist AM630 (1 μM) and was absent in CB 2 −/− mice (Fig. 4 C, a) . AM630 alone (1 μM) did not affect neuronal firing. In addition, we also tested the effects of four additional CB 2 R agonists [GW405833 (GW), SER601, CB65, and HU308] on VTA DA neuronal firing, and found that all tested CB 2 R agonists produced similar inhibitory effects on DA neuronal firing (Fig. 4 C, b ) (*P < 0.05, paired t tests). Representative AP traces and summarized group data illustrating that JWH133 altered membrane potential (MP), AP firing rate, AP initiation, AP duration, and AHP in WT mice. (F and G) Representative depolarizing current-induced AP firing and summarized data illustrating that JWH133 decreased VTA DA neuronal excitability. (H and I) Representative records and summarized data illustrating that JWH133 or GW405833 (GW) inhibited VTA DA neuronal firing in brain slices in a concentration-dependent manner. This effect was blocked by coadministration of AM630 and was absent in CB 2 −/− mice. All quantificated data are normalized to control (predrug baseline). Error bars indicate ± SEM. *P < 0.05; **P < 0.01, compared with predrug controls. Also see Fig. S6 .
Further analysis of neuronal firing patterns revealed that JWH133 significantly attenuated the AP FR (Fig. 4 D, a) , hyperpolarized the membrane potential (Fig. 4 D, b) , prolonged AP initiation latency (Fig. 4 D, b) , shortened AP duration (Fig. 4 D, c) , and increased the afterhyperpolarization potential (AHP) (Fig.  4 D, d ). Fig. 4E shows pooled data, illustrating that JWH133-induced changes in each AP parameter were statistically significant compared with pre-JWH133 baselines (*P < 0.05; **P < 0.01, paired t tests). The actual values of each AP parameter before and after JWH133 administration are presented in Table S2 . Fig. 4 F and G shows AP firing induced by injections of different intensities of current (10-50 pA) via the recording electrode, illustrating that JWH133 (1 μM) significantly shifted the input-output relationship curve to the right ( Fig. 4G ; two-way ANOVA for repeated measures over injection current, F 2,15 = 3.95, P < 0.05), suggesting reduced neuronal excitability of VTA DA neurons after JWH133 application.
CB 2 Rs Modulate DA Neuronal Activity in ex Vivo VTA Slices. We also tested the effects of JWH133 on VTA DA neuronal firing in VTA slice preparations using cell-attached patch-clamp recording techniques. In this recording mode, the intracellular environment of the recorded neurons is not interrupted. Fig. 4H shows representative records of VTA DA neuronal firing, illustrating that JWH133 significantly reduced VTA DA neuronal firing in VTA slices. Fig. 4I shows pooled data, illustrating that JWH133 and GW405833 significantly inhibited neuronal firing in a dose-dependent manner in WT mice (**P < 0.01, paired t test). This effect was blocked by AM630 (1 μM) and was absent in CB 2 −/− mice. We also examined the effects of JWH133 on GABA neuronal firing in VTA slices prepared from mice expressing GFP under the control of the GAD67 promoter (GAD67-GFP knock-in mice) (32) (Fig. S6) . We found that, unlike VTA DA neurons, VTA GABA neurons (labeled by GFP) were insensitive to JWH133 (1, 10 μM) under the same experimental conditions (Fig. S6 D,  c; F 3,36 = 0.85, P > 0.05), suggesting that CB 2 Rs predominantly modulate VTA DA, but not GABA, neuronal function.
CB 2 Rs Modulate VTA DA Neuronal Firing in Vivo. To determine whether the effects observed in ex vivo cells and brain slices can be seen in vivo, we examined the effects of systemic administration of JWH133 on VTA DA neuronal firing in anesthetized mice using single-unit recording techniques. The criteria for identification of DA neurons in vivo were the same as we reported previously (33, 34) . Fig. 5A shows the recording sites as revealed by histological examination after completion of electrophysiological recording. Fig. 5B shows a representative extracellular recording, illustrating that systemic administration of JWH133 (10 or 20 mg/kg i.p.) dose-dependently inhibited the basal FR and burst firing (BS) rate (defined as the number of burst spikes/s) in VTA DA neurons. This effect was reversed by systemic administration Error bars indicate ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001 compared with predrug controls.
of 10 mg/kg AM630. Fig. 5C shows normalized FRs over pre-JWH133 baselines, illustrating that JWH133 significantly inhibited VTA DA neuronal firing in WT and CB 1 −/− mice, but not in CB 2 −/− mice. One-way ANOVA for repeated measures over JWH133 doses revealed a significant JWH133 treatment main effect on basal FR and BS in WT mice (F 3,27 = 5.07, P < 0.001 and F 3,27 = 6.65, P < 0.01, respectively) and in CB 1 −/− mice (F 2,12 = 6.35, P < 0.05 and F 2,12 = 6.87, P < 0.05), but not in CB 2 −/− mice (Fig. 5  C, a and b) . In addition, JWH133 also significantly decreased the interspike interval coefficient of variation (ISI CV) in WT mice (from pre-JWH133 baseline of 1.0 ± 0 to 0.84 ± 0.04 after 10 mg/kg JWH133 or to 0.83 ± 0.03 after 20 mg/kg JWH133; F 3,36 = 4.03, P < 0.05), suggesting a significant alteration in the burst firing pattern of VTA DA neurons after JWH133 administration (35) .
We note that the inhibitory effect produced by JWH133 on burst firing was not completely reversed by AM630 administered after JWH133 (Fig. 5 C, b) . Therefore, we further examined the effects of AM630 pretreatment on JWH133's action in VTA DA neurons. We found that pretreatment with AM630 (10 mg/kg) completely prevented JWH133-induced reduction in basal FR, burst firing, and ISI CV (Fig. 5 D and E) , suggesting CB 2 Rmediated effects. In addition, AM630 alone slightly enhanced burst firing (Fig. 5E ), but this enhancement was not statistically significant compared with the pre-AM630 baseline (F 2,21 = 0.50, P > 0.05).
CB 2 Rs in the VTA Modulate Cocaine Self-Administration. Finally, we investigated whether activation of CB 2 Rs in the VTA alters DAregulated behavior. VTA DA neurons play a critical role in the rewarding effects of cocaine (28); thus, we examined whether microinjection of JWH133 into the VTA alters i.v. cocaine selfadministration. In this experiment, 12 WT and 12 CB 2 −/− mice were allowed daily cocaine self-administration. After 3-4 wk of daily access to cocaine (0.5 mg/kg for 3 h), most of the WT (9 of 12) and CB 2 −/− mice (8 of 12) had acquired stable cocaine selfadministration, defined as (i) at least 20 infusions per 3-h session, (ii) <20% variability in daily cocaine infusions across two consecutive sessions, and (iii) an active/inactive operant response ratio exceeding 2:1 (22, 36) .
We found that bilateral microinjections of JWH133 (1 or 3 μg/1 μL/side) into the VTA (Fig. 6 A, a) significantly reduced cocaine self-administration in WT mice, but not in CB 2 −/− mice ( Fig. 6 A, b and c). This effect was blocked by coadministration of AM630 and JWH133, whereas microinjections of AM630 alone had no effect on cocaine self-administration. One-way ANOVA for repeated measures over dose revealed a significant JWH133 treatment main effect in WT mice (F 2,16 = 4.83, P < 0.05), but not in CB 2 −/− mice (F 2,14 = 0.81, P > 0.05) (Fig. 6 A, c) . In contrast, bilateral microinjections of the same doses of JWH133 into the VTA failed to alter oral sucrose self-administration (Fig. 6 A, d) . Furthermore, bilateral microinjections of the same doses of JWH133 into a brain region adjacent to but outside and dorsal to the VTA (Fig. 6 B, a ) had no effect on cocaine selfadministration (Fig. 6 B, b) . These results suggest that activation of VTA CB 2 Rs selectively modulates cocaine, but not food, self-administration behavior.
Discussion
The major findings of the present study can be summarized as follows: (i) qRT-PCR detected low levels of CB 2 mRNA in several brain regions; (ii) ISH and IHC assays detected CB 2 mRNA and receptor expression in VTA DA neurons; (iii) activation of CB 2 Rs by JWH133 or other CB 2 agonists inhibited VTA DA neuronal firing in single dissociated neurons, VTA slices, and anesthetized animals; (iv) microinjections of JWH133 into the VTA inhibited cocaine self-administration; and (v) all of the foregoing effects of JWH133 were blocked by CB 2 R antagonism or absent in CB 2 −/− mice. Taken together, these findings from genes to behavior provide convincing evidence that brain CB 2 Rs are expressed in VTA DA neurons, where they modulate DA neuronal function and DA-regulated behavior.
CB 2 mRNA Is Expressed in Mouse Brain. Although growing evidence now suggests the presence of CB 2 Rs in brain, conclusive evidence has been lacking owing to a lack of CB 2 −/− mice and other necessary controls. Thus, whether functional CB 2 Rs are expressed in VTA DA neurons has been unclear. To fully address these issues, we used multiple experimental approaches to study CB 2 R expression and function in VTA DA neurons. We first used qRT-PCR to detect CB 2 mRNA expression in the brains of WT, CB 1 −/− , and CB 2 −/− mice. We found that three different probes (CB 2A , CB 2B , and CB 2 -KO probes) detected CB 2 mRNA in the brains of WT mice. The findings in CB 2 −/− mice depended on the probes used. When we used probes targeted at the CB 2 R gene sequences upstream and downstream from the region, the CB 2 mRNA signal was consistently detectable, whereas when we used a probe targeting the gene-deleted region, no CB 2 mRNA signal was detected. Microinjections of the same doses of JWH133 into a brain region adjacent and dorsal to the VTA (B, a) had no effect on cocaine self-administration (B, b). Up arrows indicate the last cocaine infusion allowed. All quantificated data are means ± SEM. *P < 0.05, compared with vehicle group. RN, red nucleus; SNr, substantia nigra pars reticulata.
These findings suggest that the CB 2 −/− mice used in this study are actually partial, not full, knockouts in gene structure. Although these animals lack functional CB 2 Rs, the majority of the CB 2 gene sequence is still present; thus, extreme caution is required when addressing CB 2 signaling specificity using such CB 2 −/− mice as controls.
We note that brain CB 2A and CB 2B mRNA levels are very low compared with that in CB 2 -rich spleen (∼60-fold lower for CB 2A mRNA and ∼500-fold lower for CB 2B mRNA in cortex than in spleen). This may explain why earlier ISH and RT-PCR studies failed to detect brain CB 2 mRNA, given that the experimental conditions used to detect high-density CB 2 mRNA in spleen might not be optimal for detecting low levels of CB 2 mRNA in the brain. Low densities of CB 2 mRNA in brain do not necessarily mean low levels of CB 2 R expression, however. For example, brain opioid receptor mRNA levels are generally very low, particularly in the cerebral cortex, olfactory bulb, and spinal cord (37, 38) ; however, high densities of opioid receptors are expressed in those brain regions (37, 39) . Because the CB 2 -KO probe targeting the gene-deleted region in CB 2 −/− mice detected CB 2 mRNA in WT and CB 1 −/− mice, but not in CB 2 −/− mice, we posit that the mRNA signaling detected by this probe is mCB 2 -specific.
CB 2 mRNA Is Expressed in VTA DA Neurons. The foregoing findings with the CB 2 -KO probe led us to successfully develop a mCB 2 -specific riboprobe that allowed us to use the CB 2 −/− mice as a negative control for studying CB 2 gene expression in VTA DA neurons. Using this probe, which also targets the gene-deleted region in CB 2 −/− mice, we found that CB 2 mRNA is expressed in VTA neurons in WT and CB 1 −/− mice, but not in CB 2 −/− mice. This is consistent with the foregoing findings from qRT-PCR. Furthermore, double-label CB 2 mRNA assays (by ISH) and TH assays (by IHC) detected a low-to-moderate density of CB 2 mRNA staining in TH-positive VTA DA neurons in WT mice, but not in CB 2 −/− mice, suggesting that CB 2 R mRNA is natively expressed in mouse VTA DA neurons.
To further explore these findings, we successfully developed another riboprobe (CB 2 RNAscope probe) that allowed us to readily detect very low levels of CB 2 mRNA in the VTA and other brain loci. This probe is mCB 2 -specific because it is a long riboprobe with 943 base pairs (SI Experimental Procedures) and targets a 3′ UTR sequence of the mCB 2 gene that shows no homology with CB 1 or other genes in the nucleotide sequence (Advanced Cell Diagnostics). In addition, RNAscope ISH uses a unique double RNA-specific oligonucleotide probe design strategy; thus, the chance of such Z-Z probes binding nonspecifically next to each other is very low (40) . Furthermore, the RNAscope technology uses a unique probe design strategy that allows simultaneous amplification of multiple target mRNA signals and suppression of background noise signals (40) . Therefore, it is highly sensitive to very low levels of mRNA, even a single molecule, and thus is particularly suitable for detecting CB 2 mRNA expression in the brain. Using such a probe, we detected low-tomoderate CB 2 mRNA in VTA DA neurons. This is congruent with our findings from qRT-PCR (Fig. 1) and from ISH combined with IHC ( Fig. 2A) . This probe also apparently detected CB 2 mRNA signaling in CB 2 −/− mice (Fig. 2B) , targeting the downstream 3′ UTR as distinct from the upstream gene-deleted region. These congruent findings using two different ISH assays with two different probes strongly suggest that CB 2 mRNA is expressed in VTA DA neurons. mice; however, the findings in CB 2 −/− mice depended on the epitope of the antibody. Both the NIH5633 and Alomone mCB 2 antibodies with epitopes at the receptor-deleted region in CB 2 −/− mice detected much higher densities of CB 2 R immunostaining in both VTA DA neurons and splenocytes in WT mice than in CB 2 −/− mice, whereas the Abcam rCB 2 antibody with epitope at the intact N terminal of CB 2 Rs detected similar densities of CB 2 immunostaining, supporting mCB 2 -specificity of the detected signal. We note that both the NIH5633 and Alomone antibodies should not detect CB 2 R immunostaining in CB 2 −/− mice, because they target the receptor-deleted region; however, both antibodies detected weak immunostaining in both VTA and spleen cells in CB 2 −/− mice, suggesting that they are not absolutely mCB 2 R-specific.
It has been reported that CB 2 Rs are expressed and up-regulated in microglia during neuroinflammation in humans (21, 41) . Our experiments did not reveal obvious CB 2 R immunostaining in glial cells in the VTA. To confirm this, we used a GFAP antibody and a CD11b antibody to label VTA astrocytes and microglia, respectively, and used LPS to stimulate glial cell proliferation. We observed only weak CB 2 immunostaining in GFAP-labeled astrocytes and no CB 2 immunostaining in CD11b-labeled microglia. These findings are consistent with previous reports that microglia and astrocytes may not express CB 2 Rs in healthy rats and mice (14, (41) (42) (43) . More studies are required to address it.
CB 2 R Activation Inhibits VTA DA Neuronal Firing. To determine whether CB 2 Rs expressed in VTA DA neurons are functional, we used electrophysiological methods to study the response(s) of VTA DA neurons to selective CB 2 R ligands. We explored this at three levels: single dissociated DA neurons, DA neurons in VTA slices, and DA neurons in intact anesthetized mice. We found that systemic or local (bath) administration of JWH133 or any of the four other CB 2 R agonists significantly inhibited VTA DA neuronal firing in a dose-or concentration-dependent manner in WT and CB 1 −/− mice. This inhibitory effect was reversed by pharmacologic blockade of CB 2 Rs (AM630) or was absent in CB 2 −/− mice, suggesting a CB 2 R-mediated effect. This finding is consistent with previous reports in which JWH133 or other CB 2 R agonists inhibited spontaneous and evoked neuronal firing to noxious stimuli in spinal cord and thalamus (44) (45) (46) (47) and inhibited excitatory neuronal firing in the prefrontal cortex (48) . Thus, our electrophysiological data provide direct evidence demonstrating that the expressed CB 2 Rs in VTA DA neurons are functional, and that activation of these receptors inhibits VTA DA neuronal firing and decreases VTA DA neuronal excitability.
Furthermore, we found little effect of JWH133 on neuronal firing in identified VTA GABA neurons using GAD67-GFP transgenic mice, apparently contrary to a previous report that CB 2 R agonists inhibit GABAergic synaptic transmission in cerebral cortex (49) . This finding may be related to different cellular distributions of CB 2 Rs in different brain regions.
As noted above, the burst activity of VTA DA neurons has been associated with increased vulnerability to cocaine selfadministration (50) . Consequently, we investigated whether VTA CB 2 R activation inhibits cocaine self-administration behavior. We found that microinjections of JWH133 into the VTA selectively decreased cocaine, but not sucrose, self-administration in WT and CB 1 −/− mice, but not in CB 2 −/− mice. In contrast, microinjections of the same doses of JWH133 into a dorsal brain region adjacent to the VTA failed to alter cocaine self-administration, suggesting an effect produced by activation of CB 2 Rs in the VTA, not in adjacent structures. This is consistent with our previous findings that systemic or local administration of JWH133 into the nucleus accumbens inhibits cocaine self-administration (22) , and that transgenic up-regulation of brain CB 2 Rs attenuates cocaine self-administration and cocaine-induced increased locomotion (19) . The present findings are also congruent with recent reports that brain CB 2 Rs have important roles in other DArelated functions and/or CNS disorders (12, 25, 51, 52) .
In conclusion, the present study demonstrates that CB 2 Rs are expressed in VTA DA neurons and functionally modulate DA neuronal excitability and DA-related behavior. Considering that midbrain DA neurons play important roles in brain reward, locomotion, cognition, motivation, and various goal-directed behaviors, our findings provide direct evidence supporting an important role for VTA CB 2 Rs in these actions, as well as in DA-related neurologic disorders, such as drug addiction. Thus, brain CB 2 Rs may constitute a new therapeutic target for treatment of such CNS disorders.
Experimental Procedures
Animals. Male WT, CB 1 qRT-PCR. The qRT-PCR assay of brain CB 2 mRNA levels was performed as described previously (10) . Because immune cells in blood contain a high density of CB 2 Rs, all mice used for qRT-PCR were perfused transcardially with 30-50 mL 0.9% saline under deep anesthesia, to prevent contamination of brain tissue by blood cells. Then brain and spleen were removed, and the prefrontal cortex, striatum, and midbrain were dissected. Three specific CB 2 probes were used: a CB 2A probe that recognizes the conjunction region of encoding exons 1 and 3, a CB 2B probe that recognizes the conjunction region of exons 2 and 3, and a CB 2 -KO probe that targets the gene-deleted region close to the 3′ end of exon 3 in CB 2 −/− mice. Mouse β-actin mRNA served as an endogenous control. The specific base pair sequences of the minor groove binder (MGB)-TaqMan probes and the primers used to detect CB 2 and β-actin mRNAs are listed in Table S1 .
ISH.
CB 2 ISH and TH IHC Assays. Total RNA was isolated from C57BL/6J mouse brain samples using the Qiagen RNeasy Mini Kit according to the manufacturer's protocol. cDNA was synthesized from total RNA using the Bio-Rad iScript cDNA Synthesis Kit. For CB 2 -mRNA riboprobe synthesis, oligonucleotide primers were designed specifically to detect the deleted mCB 2 mRNA region in CB 2 −/− mice: forward primer 5′-AGCTCGGATGCGGCTAGAC-3′ and reverse primer 5′-AGGCTGTGGCCCATGAGA-3′. The template cDNA sequence of CB 2 Rs was obtained from GenBank (ncbi.nlm.nih.gov/). RNAscope ISH Assays. Both the CB 2 and TH RNA probes were designed and provided by Advanced Cell Diagnostics (Hayward, CA). The CB 2 -specific RNA probe was designed to detect the 3′ UTR (1877-2820 bp) of the Mus Cnr2 mRNA sequence (NM_009377.1, C1 channel) (Fig. 2B, a) . The TH RNA probe was designed to detect 483-1,603 bp of Mus musculus TH mRNA sequence (NM_009924.3, C2 channel). Complete experimental methods for CB 2 -ISH assays, along with TH-IHC and RNAscope ISH assays, are described in SI Experimental Procedures.
IHC Assays. Three CB 2 R antibodies were used to detect CB 2 R expression in VTA DA neurons in WT, CB 1 −/− , and CB 2 −/− mice. Complete experimental methods for IHC assays are described in SI Experimental Procedures.
Electrophysiology Studies. Standard electrophysiological methods were used to record VTA DA neuronal responses to selective CB 2 R ligands in single dissociated VTA DA neurons (using perforated patch-clamp recording), in VTA slices (using cell-attached patch-clamp recording), and in anesthetized mice (using extracellular single-unit recording). Complete electrophysiological methods are described in SI Experimental Procedures.
Intravenous Cocaine Self-Administration. Animal surgery, cocaine or sucrose self-administration, and intracranial microinjection procedures were as described previously (22) . In brief, after stable cocaine or sucrose self-administration was achieved, subjects randomly received one microinjected dose of intra-VTA JWH133 (1 or 3 μg/side), AM630 (3 μg/side), a mixed solution of AM630 (3 μg/side) and JWH133 (3 μg/side), or vehicle (Tocrisolve 100) 30 min before cocaine or sucrose self-administration. After each test, animals underwent an additional 3-5 d of self-administration until the baseline response rate was reestablished before the next dose was tested. Cannula placements were verified after completion of the experiments by standard histological and anatomic localization techniques.
Data Analyses. All data are presented as means ± SEM. One-way or two-way ANOVA (SigmaStat software) was used to analyze the significance of the effects of JWH133 or other drugs on neuronal firing and cocaine self-administration. Individual group comparisons were carried out using the Student NewmanKeuls method. In addition, paired t tests were used to analyze some electrophysiological data, as described previously (30, 31) . FRs and burst firing were determined every 10 s, as described previously (57, 58) .
